0.99

7.90% 0.0725

After Hours: .96 -0.03 -3.03%

Lineage Cell Therapeutics Inc (LCTX)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Lineage Cell Therapeutics Inc stock is traded at $0.99, with a volume of 1.36M. It is up +7.90% in the last 24 hours and down -6.60% over the past month. Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.

Previous Close:

$0.9175

Open:

$0.9212

24h Volume:

1.36M

Relative Volume:

0.87

Market Cap:

$250.38M

Revenue:

$14.78M

Net Income/Loss:

$-64.01M

P/E Ratio:

-3.4459

EPS:

-0.2873

Net Cash Flow:

$-22.59M

1W Performance:

-3.88%

1M Performance:

-6.60%

6M Performance:

-39.26%

1Y Performance:

-45.30%

1-Day Range:

$0.918

$0.9994

1-Week Range:

$0.8902

$1.025

52-Week Range:

$0.8823

$2.09

Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile

Name

Lineage Cell Therapeutics Inc

Sector

Healthcare (1051)

Industry

Biotechnology (593)

Phone

510-871-4188

Address

2173 Salk Avenue, Suite 200, Carlsbad, CA

Employee

Twitter

@LineageCell

Next Earnings Date

2026-11-05

Latest SEC Filings

LCTX's Discussions on Twitter

Compare LCTX vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LCTX Lineage Cell Therapeutics Inc	0.99	250.38M	14.78M	-64.01M	-22.59M	-0.2873
VRTX Vertex Pharmaceuticals Inc	508.74	128.95B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	236.50	94.42B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	796.35	81.99B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	846.50	53.23B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	374.30	42.34B	5.76B	514.49M	1.10B	4.4813

Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-28-26	Initiated	Canaccord Genuity	Buy
Aug-20-24	Initiated	Craig Hallum	Buy
Nov-02-22	Initiated	Robert W. Baird	Outperform
Jun-14-22	Initiated	B. Riley Securities	Buy
Aug-19-21	Initiated	Noble Capital Markets	Outperform
Mar-31-21	Initiated	Cantor Fitzgerald	Overweight

View All

Lineage Cell Therapeutics Inc Stock (LCTX) Latest News

Oct 12, 2026

Transcript: Lineage Cell Therapeutics Q2 2026 Earnings Conference Call - Benzinga

Oct 12, 2026

Sep 26, 2026

LCTX Jumps As Lineage Wins Long-Dated AlloSCOPE Patent - timothysykes.com

Sep 26, 2026

Sep 25, 2026

B. Riley Securities Maintains Lineage Cell Therapeutics(LCTX.US) With Buy Rating, Maintains Target Price $4 - Moomoo

Sep 25, 2026

Sep 08, 2026

Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform - BioSpace

Sep 08, 2026

Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE 5D Manufacturing Platform - Investing News Network

Sep 08, 2026

LCTX Looks 6.9% Undervalued on GF Value™ as Stem Cell Patent Boo - GuruFocus

Sep 08, 2026

Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform - Business Wire

Sep 08, 2026

Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform - Yahoo Finance

Sep 08, 2026

Sep 01, 2026

Lineage Cell Therapeutics: Balancing An Out-Licensed Pipeline Against Clinical Risk - Seeking Alpha

Sep 01, 2026

Aug 27, 2026